OBJECTIVE: To assess the impact of rheumatoid arthritis (RA) on absence time, absence payments, and other health benefit costs from the perspective of US employers. METHODS: Retrospective regression-controlled analysis of a database containing US employees' administrative health care and payroll data for those who were enrolled for at least 1 year in an employer-sponsored health insurance plan. RESULTS: Employees with RA (N = 2705) had $4687 greater average annual medical and prescription drug costs (P < 0.0001) and $525 greater (P < 0.05) indirect costs (because of sick leave, short- and long-term disability, and workers' compensation absences) than controls (N = 338,035). Compared with controls, the employees with RA used an additional 3.58 annual absence days, including 1.2 more sick leave and 1.91 more short-term disability days (both P < 0.0001). CONCLUSION: Employees with RA have greater costs across all benefits than employees without RA.
OBJECTIVE: To assess the impact of rheumatoid arthritis (RA) on absence time, absence payments, and other health benefit costs from the perspective of US employers. METHODS: Retrospective regression-controlled analysis of a database containing US employees' administrative health care and payroll data for those who were enrolled for at least 1 year in an employer-sponsored health insurance plan. RESULTS: Employees with RA (N = 2705) had $4687 greater average annual medical and prescription drug costs (P < 0.0001) and $525 greater (P < 0.05) indirect costs (because of sick leave, short- and long-term disability, and workers' compensation absences) than controls (N = 338,035). Compared with controls, the employees with RA used an additional 3.58 annual absence days, including 1.2 more sick leave and 1.91 more short-term disability days (both P < 0.0001). CONCLUSION: Employees with RA have greater costs across all benefits than employees without RA.
Authors: Bruce C M Wang; Ping-Ning Hsu; Wesley Furnback; John Ney; Ya-Wen Yang; Chi-Hui Fang; Chao-Hsiun Tang Journal: Drugs Real World Outcomes Date: 2016-03
Authors: Regina Rendas-Baum; Mark Kosinski; Amitabh Singh; Charles A Mebus; Bethany E Wilkinson; Gene V Wallenstein Journal: Rheumatology (Oxford) Date: 2017-08-01 Impact factor: 7.580
Authors: A M Orbai; S M Reddy; N Dennis; R Villacorta; S Peterson; L Mesana; S D Chakravarty; I Lin; C S Karyekar; Y Wang; M Pacou; J Walsh Journal: Clin Rheumatol Date: 2021-07-21 Impact factor: 2.980